Market Closed -
Hong Kong S.E.
04:08:22 2024-05-10 am EDT
|
5-day change
|
1st Jan Change
|
6.75
HKD
|
0.00%
|
|
-1.89%
|
-11.65%
|
Fiscal Period: December |
2022
|
---|
Capitalization
1 |
8,383
|
Enterprise Value (EV)
1 |
7,616
|
P/E ratio
|
-1.67
x
|
Yield
|
-
|
Capitalization / Revenue
|
14,773,952
x
|
EV / Revenue
|
13,423,339
x
|
EV / EBITDA
|
-17.6
x
|
EV / FCF
|
-49,450,242
x
|
FCF Yield
|
-0%
|
Price to Book
|
8.92
x
|
Nbr of stocks (in thousands)
|
223,327
|
Reference price
2 |
37.54
|
Announcement Date
|
4/28/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
60.26
|
567.4
|
EBITDA
1 |
-303.3
|
-516.8
|
-431.7
|
EBIT
1 |
-304.5
|
-520.5
|
-439.6
|
Operating Margin
|
-
|
-863.81%
|
-77.47%
|
Earnings before Tax (EBT)
1 |
-635.4
|
-1,462
|
-1,052
|
Net income
1 |
-635.4
|
-1,434
|
-1,024
|
Net margin
|
-
|
-2,379.84%
|
-180.54%
|
EPS
2 |
-13.93
|
-36.72
|
-22.52
|
Free Cash Flow
|
-
|
-192.3
|
-154
|
FCF margin
|
-
|
-319.13%
|
-27.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
11/28/22
|
11/28/22
|
4/28/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net Debt
1 |
1,252
|
2,367
|
-
|
Net Cash position
1 |
-
|
-
|
766
|
Leverage (Debt/EBITDA)
|
-4.126
x
|
-4.58
x
|
-
|
Free Cash Flow
|
-
|
-192
|
-154
|
ROE (net income / shareholders' equity)
|
-
|
82.5%
|
153%
|
ROA (Net income/ Total Assets)
|
-
|
-41.8%
|
-23%
|
Assets
1 |
-
|
3,431
|
4,460
|
Book Value Per Share
2 |
-27.80
|
-61.40
|
4.210
|
Cash Flow per Share
2 |
9.080
|
21.20
|
3.110
|
Capex
1 |
11.1
|
43.9
|
54
|
Capex / Sales
|
-
|
72.8%
|
9.51%
|
Announcement Date
|
11/28/22
|
11/28/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -11.65% | 196M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|